Navigation Links
BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
Date:2/6/2009

pharmacokinetic (PK) and pharmacodynamic (PD) study. The interim analysis was conducted on data from an exploratory Phase 2 single-arm, open-label program in patients with CLL who failed previous treatment. No partial or complete responses were observed, but five out of 13 patients who were administered 200 mg of Forodesine HCl once-daily had substantial reductions in malignant lymphocytes. Forodesine HCl was generally safe and well-tolerated at the 200 mg once-daily dose. The PK and PD study evaluated the effect of seven days of 200 mg Forodesine HCl dosed either once-daily or twice-daily in healthy volunteers. The study demonstrated substantially increased drug exposure and PD effect in volunteers administered Forodesine HCl 200 mg twice-daily compared to volunteers administered Forodesine HCl 200 mg once-daily. Based on both the CLL interim analysis and the PK and PD study results, the dosing regimen in the ongoing Phase 2 CLL study was amended to evaluate 200 mg Forodesine HCl twice-daily. The Company expects to provide an update on this study by the end of 2009.

BCX-4208

  • A poster entitled, "A Phase 2 Study of the Purine Nucleoside Phosphorylase (PNP) Inhibitor RO5092888 (BCX-4208) in Patients with Moderate to Severe Chronic Plaque Psoriasis: Safety, Tolerability and Lymphocyte Effects" was presented at the 50th American Society of Hematology (ASH) Annual Meeting and Exposition, which was held in San Francisco, December 6-9, 2008. The poster highlighted results from a Phase 2a study that investigated the safety and tolerability of BCX-4208 in patients with moderate to severe chronic plaque psoriasis. Results showed BCX-4208 was safe and well tolerated.

  • BioCryst also presented a poster at ASH entitled, "BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor is a Novel, Potent Orally Active Anti T- and B-Cell Agen
    '/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/22/2014)... -- Research and Markets  has announced the addition ... Application, Geography - Global Analysis and Forecast (2014 - ... Organic electronics, also called as polymer electronics or plastic ... with small conductive molecules and electrically conductive polymers. It ... are carbon based, made using synthetic strategies developed in ...
(Date:10/20/2014)... 20, 2014 The report “Pharmacy ... Systems, Packaging and Labeling Systems, Table-top Counters) by ... Global Forecasts & Trends to 2019” analyzes and ... in North America, Europe, Asia-Pacific, and the Rest ... tables and 30 figures spread through 300 pages ...
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... a new marketing "mashup" that integrates web ... the sole purpose of generating leads, today ... ChemBridge Corp., a leader in discovery chemistry ... biotech and research institutions. ChemBridge will retain ...
... Panda Ethanol Inc. (OTC Bulletin Board: PDAE) today announced ... petition for relief under Chapter 11 of the United ... for the Northern District of Texas. The company intends ... pursuant to a Section 363 sale process approved by ...
... TARRYTOWN, N.Y., Jan. 23 Aerolase Corporation, a ... skin treatments, today announced that sales increased dramatically ... offerings in the aesthetic laser market helped to ... Aerolase executives."December 2008 was a record sales month ...
Cached Biology Technology:HiveMind Marketing to Enhance Search Results for Chemistry Solutions Leader ChemBridge 2HiveMind Marketing to Enhance Search Results for Chemistry Solutions Leader ChemBridge 3HiveMind Marketing to Enhance Search Results for Chemistry Solutions Leader ChemBridge 4Panda Ethanol's Hereford, Texas Subsidiary Files Voluntary Chapter 11 2Panda Ethanol's Hereford, Texas Subsidiary Files Voluntary Chapter 11 3Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers 2Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers 3
(Date:10/17/2014)... Rockville, MD – Accurate knowledge regarding Ebola is critical ... current risk of hazardous global outbreak and epidemic. The ... has launched a special issue, Ebola Virus and Public ... with necessary knowledge in this critical societal moment. ... Primer on Ebola for Clinicians . The primer was ...
(Date:10/17/2014)... German . To ... treating overdoses, doctors are often limited to supportive therapy such ... a combination of drugs involved. So what can be done ... pills? ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical ... this question. "The task was to develop an agent that ...
(Date:10/16/2014)... managers have a new synthesis of recent research findings ... forests in the two states. , The Ecology ... and Washington: A Synthesis of the Relevant Biophysical Science ... report published by the U.S. Forest Service,s Pacific Northwest ... from managers for a synthesis of the large body ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3New report synthesizes best available science on management of moist mixed-conifer forests 2
... researchers have developed a highly effective method for converting CO2 ... for vehicles. The team led by Professor Frdric-Georges Fontaine presents ... the Journal of the American Chemical Society . ... into carbon dioxide in a single step using energy-efficient processes ...
... survival and development, and its safety is an important ... to measure the quality of people,s lives in a ... Chinese food poisoning remained to be microbial pathogens, ranking ... and highly pathogenic pathogens include Listeria monocytogenes , ...
... Mercy Medical Center recently implemented advanced clinical laboratory ... (HbA 1c ) diabetes testing, as well as analysis ... platelet counts. The new system enables the hospital to ... their patients, which can improve treatment decisions.   ...
Cached Biology News:Too green to be true? Researchers develop highly effective method for converting CO2 into methanol 2Recent progress in gene-sensing strategies for rapid detection of foodborne pathogens 2Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies 2Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies 3Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies 4
... Note: Protein determined by Biuret Physical form: ... Tris-HCl, pH 7.6, 1 mM MgCl 2 ... Preparation Unit Definition: One unit will hydrolyze ... at pH 9.8 at 37 C. • ...
... Varioskan is a high performance ... dispenser and incubator. With the advanced ... and reliability for drug discovery assay ... for fluorescence intensity, time-resolved fluorescence and ...
Immulon 2 HB 1x8 Strip assembled, C-bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
... RCT series of refrigerated cold traps offers ... of low volatility/aqueous solvents or high volatility ... other vacuum concentrators/centrifugal evaporators. Also used for ... such as used in electron microscopes. Can ...
Biology Products: